SB490
Concerning Coverage For Genetic Testing For Inherited Cancer Mutations; And To Create The Genetic Testing Act.
Last Action (May 1, 2023): Sine Die adjournment
Sponsors
AI-Generated Summary
Senate Bill 490 creates the 'Genetic Testing Act' in Arkansas, which mandates that specific health benefit plans must provide coverage for genetic testing for inherited cancer mutations. Under the bill, coverage is required for enrollees with a personal or family history of breast cancer, provided the testing is recommended by a healthcare professional. Additionally, the act requires coverage for evidence-based screenings for enrollees identified as having an inherited cancer risk, in accordance with nationally recognized clinical practice guidelines. The bill explicitly prohibits insurers from applying cost-sharing requirements, such as deductibles or coinsurance, to these specific services. The legislation defines key terms including 'healthcare insurer,' 'genetic testing,' and 'nationally recognized clinical practice guidelines' to ensure standardized application. It provides exemptions for certain plans, including Medicaid, workers' compensation, state employee plans, and limited-benefit insurance products. The act aims to ensure that high-risk individuals can access necessary preventative genetic diagnostics without financial barriers.
Potential Impact Analysis
Who Might Benefit?
The primary beneficiaries are patients who have a personal or family history of breast cancer and other individuals identified as being at high risk for inherited cancer mutations. By removing cost-sharing barriers, this bill makes preventative genetic testing and subsequent evidence-based cancer screenings more financially accessible for these enrollees. Furthermore, healthcare professionals benefit by having a clearer framework for recommending clinical diagnostic services for their patients.
Who Might Suffer?
Health insurance issuers, health maintenance organizations, and hospital and medical service corporations regulated by the state would be negatively impacted. These entities are required to expand their coverage mandates and are prohibited from collecting deductibles, coinsurance, or other out-of-pocket payments for these genetic tests and screenings, which may increase their operational costs and impact premium rates. Employers or individuals purchasing private health insurance plans may also face higher insurance premiums as insurers adjust to the increased cost of mandatory coverage.
Get Notified
Receive an email when this bill's status changes.